SunTrust analyst Joel Fishbein keeps his Buy rating on Splunk (SPLK) and New Relic (NEWR) while raising their respective price target to $190 from $175 and to $85 from $80 as part of his broader 2020 Infrastructure Software Outlook research note. The analyst contends that both companies have recently made strategic decisions that address key issues in their business while positioning the companies for strong returns in 2020. For Splunk, Fishbein says the concerns around the company's transition to a recurring revenue model were alleviated by the company's ARR and RPO metrics as well as operating cash flow forecast of $1B for FY23. For New Relic, the analyst contends that while the company's Q2 deferred revenue and billings were softer than expected, its 112% net retention rate indicates that its new product adoption has started to take hold.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).